BACKGROUND: The US prevalence of reduced estimated glomerular filtration rate (eGFR) based on serum creatinine level increased during the decade ending in 2002. National Health and Nutrition Examination Survey (NHANES) cystatin C measurements recently were calibrated to the international standard, allowing for an independent test of the trend in prevalence of reduced eGFR using cystatin C level. STUDY DESIGN: Cross-sectional surveys performed during 2 periods. SETTING & PARTICIPANTS: Nationally representative subsamples of adult participants from NHANES III (1988-1994) and the NHANES 1999-2002 surveys. PREDICTOR: Survey period. OUTCOMES: Prevalence of reduced GFR, defined as eGFR <60 mL/min/1.73 m² based on levels of serum creatinine, cystatin C, or both (eGFRcr, eGFRcys, and eGFRcr-cys), using estimating equations developed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). MEASUREMENTS: Serum cystatin C level, measured from stored samples in 2006, calibrated to the international standard in 2012. RESULTS: Between 1988-1994 and 1999-2002, the prevalence of reduced eGFRcr, eGFRcys, and eGFRcr-cys increased from 4.7% (95% CI, 4.1%-5.3%) to 6.5% (95% CI, 5.9%-7.1%) (P < 0.001), from 5.5% (95% CI, 4.6%-6.5%) to 8.7% (95% CI, 7.5%-10.0%) (P < 0.001), and from 4.4% (95% CI, 3.7%-5.2%) to 7.1% (95% CI, 6.2%-8.0%) (P < 0.001), respectively. The higher prevalence of reduced GFR in the later period was observed in all subgroups of age, race, sex, and GFR categories. After adjusting for changes in the US population by age, sex, race, diabetes, hypertension, and body mass index, prevalence ratios of reduced GFR in the later versus earlier survey were 1.24 (95% CI, 1.09-1.45), 1.34 (95% CI, 1.15-1.67), and 1.33 (95% CI, 1.17-1.65) using eGFRcr, eGFRcys, and eGFRcr-cys, respectively. LIMITATIONS: Likely underascertainment of persons with GFR <15 mL/min/1.73 m²; GFR was estimated and not measured; comparability of laboratory assays based on a calibration subsample. CONCLUSIONS: The prevalence of reduced eGFRcys in the US civilian noninstitutionalized population increased between 1988-1994 and 1999-2002, confirming the increase observed in the prevalence of reduced eGFRcr.
BACKGROUND: The US prevalence of reduced estimated glomerular filtration rate (eGFR) based on serum creatinine level increased during the decade ending in 2002. National Health and Nutrition Examination Survey (NHANES) cystatin C measurements recently were calibrated to the international standard, allowing for an independent test of the trend in prevalence of reduced eGFR using cystatin C level. STUDY DESIGN: Cross-sectional surveys performed during 2 periods. SETTING & PARTICIPANTS: Nationally representative subsamples of adult participants from NHANES III (1988-1994) and the NHANES 1999-2002 surveys. PREDICTOR: Survey period. OUTCOMES: Prevalence of reduced GFR, defined as eGFR <60 mL/min/1.73 m² based on levels of serum creatinine, cystatin C, or both (eGFRcr, eGFRcys, and eGFRcr-cys), using estimating equations developed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). MEASUREMENTS: Serum cystatin C level, measured from stored samples in 2006, calibrated to the international standard in 2012. RESULTS: Between 1988-1994 and 1999-2002, the prevalence of reduced eGFRcr, eGFRcys, and eGFRcr-cys increased from 4.7% (95% CI, 4.1%-5.3%) to 6.5% (95% CI, 5.9%-7.1%) (P < 0.001), from 5.5% (95% CI, 4.6%-6.5%) to 8.7% (95% CI, 7.5%-10.0%) (P < 0.001), and from 4.4% (95% CI, 3.7%-5.2%) to 7.1% (95% CI, 6.2%-8.0%) (P < 0.001), respectively. The higher prevalence of reduced GFR in the later period was observed in all subgroups of age, race, sex, and GFR categories. After adjusting for changes in the US population by age, sex, race, diabetes, hypertension, and body mass index, prevalence ratios of reduced GFR in the later versus earlier survey were 1.24 (95% CI, 1.09-1.45), 1.34 (95% CI, 1.15-1.67), and 1.33 (95% CI, 1.17-1.65) using eGFRcr, eGFRcys, and eGFRcr-cys, respectively. LIMITATIONS: Likely underascertainment of persons with GFR <15 mL/min/1.73 m²; GFR was estimated and not measured; comparability of laboratory assays based on a calibration subsample. CONCLUSIONS: The prevalence of reduced eGFRcys in the US civilian noninstitutionalized population increased between 1988-1994 and 1999-2002, confirming the increase observed in the prevalence of reduced eGFRcr.
Authors: Michael G Shlipak; Ronit Katz; Mark J Sarnak; Linda F Fried; Anne B Newman; Catherine Stehman-Breen; Stephen L Seliger; Brian Kestenbaum; Bruce Psaty; Russell P Tracy; David S Siscovick Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: Michael G Shlipak; Christina L Wassel Fyr; Glenn M Chertow; Tamara B Harris; Stephen B Kritchevsky; Frances A Tylavsky; Suzanne Satterfield; Steven R Cummings; Anne B Newman; Linda F Fried Journal: J Am Soc Nephrol Date: 2005-11-02 Impact factor: 10.121
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Anna Köttgen; Elizabeth Selvin; Lesley A Stevens; Andrew S Levey; Frederick Van Lente; Josef Coresh Journal: Am J Kidney Dis Date: 2008-03 Impact factor: 8.860
Authors: Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey Journal: Am J Kidney Dis Date: 2008-03 Impact factor: 8.860
Authors: Elizabeth Selvin; Jane Manzi; Lesley A Stevens; Frederick Van Lente; David A Lacher; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2007-12 Impact factor: 8.860
Authors: Lesley A Stevens; Christopher H Schmid; Tom Greene; Liang Li; Gerald J Beck; Marshall M Joffe; Marc Froissart; John W Kusek; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: Kidney Int Date: 2008-12-31 Impact factor: 10.612
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Jinnie J Rhee; FeiFei Qin; Haley K Hedlin; Tara I Chang; Chloe E Bird; Oleg Zaslavsky; JoAnn E Manson; Marcia L Stefanick; Wolfgang C Winkelmayer Journal: Am J Clin Nutr Date: 2015-12-09 Impact factor: 7.045
Authors: Benjamin Lazarus; Yuan Chen; Francis P Wilson; Yingying Sang; Alex R Chang; Josef Coresh; Morgan E Grams Journal: JAMA Intern Med Date: 2016-02 Impact factor: 21.873
Authors: Daniel Murphy; Charles E McCulloch; Feng Lin; Tanushree Banerjee; Jennifer L Bragg-Gresham; Mark S Eberhardt; Hal Morgenstern; Meda E Pavkov; Rajiv Saran; Neil R Powe; Chi-Yuan Hsu Journal: Ann Intern Med Date: 2016-08-02 Impact factor: 25.391
Authors: Cristina M Arce; Jinnie J Rhee; Katharine L Cheung; Haley Hedlin; Kristopher Kapphahn; Nora Franceschini; Roberto S Kalil; Lisa W Martin; Lihong Qi; Nawar M Shara; Manisha Desai; Marcia L Stefanick; Wolfgang C Winkelmayer Journal: Am J Kidney Dis Date: 2015-09-01 Impact factor: 8.860